Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy

• US 6,207,648 B1
• Filed: 07/17/1998
• Issued: 03/27/2001
• Est. Priority Date: 07/24/1997
• Status: Expired due to Fees

• Current Assignee: Trustees of Boston University
• Original Assignee: Trustees of Boston University
• Inventors: Waxman, David J., Chen, Ling
• Primary Examiner(s): Clark, Deborah J.
• Assistant Examiner(s): CHEN, SHIN LIN
• Application Number:
  US09/118,179
• Time in Patent Office: 984 Days
• Field of Search: 514/44, 435/320.1, 435/455, 536/23.2, 536/23.4
• US Class Current: 514/44.00R
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/138 Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377
• CPC Class Codes: A61K 31/166 having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• CPC Class Codes: A61K 31/341 not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• CPC Class Codes: A61K 31/655 Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 9/0042 NADPH-cytochrome P450 reductase (1.6.2.4)
• CPC Class Codes: C12N 9/0077 with a reduced iron-sulfur protein as one donor (1.14.15)
• CPC Class Codes: C12Y 106/02004 NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods of killing neoplastic cells are provided. The invention relates to the use of NADPH-cytochrome P450 reductase (RED) gene transfer in combination with cytochrome P450 gene transfer to enhance the sensitivity of tumor cells to anti-cancer drugs that are activated by P450 enzymes. The use of bioreductive drugs that are activated by RED and/or cytochrome P450, in this paradigm, is also provided.

Claims

1. A method for killing neoplastic cells in a mammal, said method comprising:

(a) delivering a vector to said neoplastic cells, said vector comprising the nucleotide coding sequence of a gene encoding cytochrome P450 and the nucleotide coding sequence of a gene encoding NADPH-P450 reductase (RED);

(b) treating said neoplastic cells with a chemotherapeutic agent that is activated by the product of said cytochrome P450 gene; and

(c) killing said neoplastic cells.

2. The method of claim 1, wherein said cytochrome P450 gene is a mammalian gene.

3. The method of claim 2, wherein said cytochrome P450 gene is P450 1A1, P450 1A2, P450 1B1, P450 2B1, P450 2B2, P450 2B4, P450 2B5, P450 2B6, P450 2B11, P450 2A6, P450 2C6, P450 2C8, P450 2C9, P450 2C11, P450 2C18, P450 2C19, P450 2D6, P450 2E1, P450 3A4, P450 3A5, P450 3A7, or P4504B1.

4. The method of claim 1, wherein said chemotherapeutic agent is cyclophosphamide, ifosfamide, dacarbazine, procarbazine, thio-TEPA, etoposide (VP-16), 4-ipomeanol, 2-aminoanthracene, or tamoxifen.

5. The method of claim 1, wherein said cytochrome P450 gene is P450 2B1, P450 2B6, or P450 2C18, and said chemotherapeutic agent is cyclophosphamide.

6. The method of claim 1, wherein said cytochrome P450 gene is P450 2B1 or P450 3A4, and said chemotherapeutic agent is ifosfamide.

7. The method of claim 1, wherein said vector is a viral vector.

8. The method of claim 7, wherein said viral vector is derived from retrovirus, adenovirus, adeno-associated virus, herpes virus, poliovirus, papillomavirus, or lentivirus.

9. The method of claim 8, wherein said viral vector is derived from retrovirus or adenovirus.

10. The method of claim 1, wherein said vector is non-viral.

11. The method of claim 10, wherein said non-viral vector is a tumor targeted bacterial vector, cationic liposome, a fusogenic liposome, a DNA-adenovirus conjugate, a DNA-protein complex, a non-viral T7 autogene vector, the direct injection of nucleic acid, particle-mediated gene transfer, receptor-mediated gene transfer, starburst polyamidoamine dendrimers, a cationic peptide, mammalian artificial chromosome, endothelial cell, or macrophage.

12. The method of claim 1, wherein said vector includes an internal ribosome entry site (IRES) sequence to achieve coordinate expression of said cytochrome P450 gene and said NADPH-P450 reductase (RED) gene.

13. The method of claim 1, wherein said cytochrome P450 nucleotide coding sequence and said NADPH-P450 reductase (RED) nucleotide coding sequence are associated in frame to encode a fusion protein.

14. The method of claim 1, further comprising treating said neoplastic cells with a bioreductive drug.

15. The method of claim 14, wherein said bioreductive drug is a nitroimidazole, a nitroaromatic, a quinone, an aliphatic, aromatic, or heterocyclic N-oxide, or a bioreducible DNA alkylator, that is capable of undergoing bioreductive activation catalyzed by cytochrome P450, NADPH-P450 reductase (RED), or both cytochrome P450 and RED.

16. The method of claim 15, wherein said bioreductive drug is Adriamycin, porfiromycin, mitomycin C, tirapazamine, indoloquinone E09, aziridinylnitroimidazole RB6145, dinitrophenylaziridine (CB1954), 2, 3, 5, 6-tetramethylbenzoquinone (TMQ), diaziquone (AZQ), the intercalator amine N-oxide AQ4N, the bioreducible DNA alkylator NSC646394 or the bioreducible DNA alkylator NSC658926.

17. The method of claim 16, wherein said bioreductive drug is tirapazamine.

18. The method of claim 1, further comprising systemically administering to said mammal an agent that will decrease the activity or expression level of hepatic P450 reductase (RED).

19. The method of claim 10, wherein said agent is an anti-thyroid drug.

20. The method of claim 19, wherein said anti-thyroid drug is methimazole or propylthiouracil.

21. The method of claim 20, wherein said anti-thyroid drug is methimazole.

22. The method of claim 1, wherein said vector further comprises the HSV-TK gene and said neoplastic cells are further treated with ganciclovir.

23. The method of claim 1, wherein said vector further comprises the bacterial cytosine deaminase (CD) gene and said neoplastic cells are further treated with 5-fluorocytosine.

24. The method of claim 1, wherein said vector further comprises a cancer therapeutic gene selected from the group consisting of tumor suppressor genes, apoptotic factor genes, and cytokine genes.

25. A method for killing neoplastic cells in a mammal, said method comprising:

(a) delivering two vectors to said neoplastic cells;

one vector comprising the nucleotide coding sequence of a gene encoding cytochrome P450, the other vector comprising the nucleotide coding sequence of a gene encoding NADPH-P450 reductase (RED);

(b) treating said neoplastic cells with a chemotherapeutic agent that is activated by the product of said cytochrome P450 gene; and

(c) killing said neoplastic cells.

26. The method of claim 25, wherein said vector comprising a cytochrome P450 gene and said vector comprising a RED gene are both viral vectors or both non-viral vectors.

27. The method of claim 25, wherein said vector comprising a cytochrome P450 gene and said vector comprising a RED gene are either viral or non-viral vectors.

28. The method of claim 25, wherein said cytochrome P450 gene is a mammalian gene.

29. The method of claim 28, wherein said cytochrome P450 gene is P450 1A1, P450 1A2, P450 1B1, P450 2B1, P450 2B2, P450 2B4, P450 2B5, P450 2B6, P450 2B11, P450 2A6, P450 2C6, P450 2C8, P450 2C9, P450 2C11, P450 2C18, P450 2C1 9, P450 2D6, P450 2E1, P450 3A4, P450 3A5, P450 3A7, or P450 4B1.

30. The method of claim 25, wherein said chemotherapeutic agent is cyclophosphamide, ifosfamide, dacarbazine, procarbazine, thio-TEPA, etoposide (VP-16), 4-ipomeanol, 2-aminoanthracene, or tamoxifen.

31. The method of claim 25, wherein said cytochrome P450 gene is P450 2B1, P450 2B6, or P450 2C18, and said chemotherapeutic agent is cyclophosphamide.

32. The method of claim 25, wherein said cytochrome P450 gene is P450 2B1 or P450 3A4, and said chemotherapeutic agent is ifosfamide.

33. The method of claim 25, further comprising treating said neoplastic cells with a bioreductive drug.

34. The method of claim 33, wherein said bioreductive drug is a nitroimidazole, a nitroaromatic, a quinone, an aliphatic, aromatic, or heterocyclic N-oxide, or a bioreducible DNA alkylator, that is capable of undergoing bioreductive activation catalyzed by cytochrome P450, NADPH-P450 reductase (RED), or both cytochrome P450 and RED.

35. The method of claim 34, wherein said bioreductive drug is Adriamycin, porfiromycin, mitomycin C, tirapazamine, indoloquinone E09, aziridinylnitroimidazole RB6145, dinitrophenylaziridine (CB1954), 2, 3, 5, 6-tetramethylbenzoquinone (TMQ), diaziquone (AZQ), the intercalator amine N-oxide AQ4N, the bioreducible DNA alkylator NSC646394 or the bioreducible DNA alkylator NSC658926.

36. The method of claim 35, wherein said bioreductive drug is tirapazamine.

37. The method of claim 25, further comprising systemically administering to said mammal an agent that will decrease the activity or expression level of hepatic P450 reductase (RED).

38. The method of claim 37, wherein said agent is an anti-thyroid drug.

39. The method of claim 38, wherein said anti-thyroid drug is methimazole or propylthiouracil.

40. The method of claim 39, wherein said anti-thyroid drug is methimazole.

41. The method of claim 25, wherein said vector further comprises the HSV-TK gene and said neoplastic cells are further treated with ganciclovir.

42. The method of claim 25, wherein said vector further comprises the bacterial cytosine deaminase (CD) gene and said neoplastic cells are further treated with 5-fluorocytosine.

43. The method of claim 25, wherein said vector further comprises a cancer therapeutic gene selected from the group consisting of tumor suppressor genes, apoptotic factor genes, and cytokine genes.

44. A method for killing neoplastic cells in a mammal, said method comprising:

(a) delivering a vector to said neoplastic cells, said vector comprising the nucleotide coding sequence of a gene encoding cytochrome P450 and the nucleotide coding sequence of a gene encoding NADPH-P450 reductase (RED);

(b) treating said neoplastic cells with a bioreductive drug; and

(c) killing said neoplastic cells.

45. The method of claim 44, wherein said cytochrome P450 gene is P450 1A1, P450 1A2, P450 1B1, P450 2B1, P450 2B2, P450 2B4, P450 2B5, P450 2B6, P450 2B11, P450 2A6, P450 2C6, P450 2C8, P450 2C9, P450 2C11, P450 2C18, P450 2C19, P450 2D6, P450 2E1,P450 3A4, P450 3A5, P450 3A7, or P450 4B1.

46. The method of claim 44, wherein said bioreductive drug is a nitroimidazole, a nitroaromatic, a quinone, an aliphatic, aromatic, or heterocyclic N-oxide, or a bioreducible DNA alkylator, that is capable of undergoing bioreductive activation catalyzed by cytochrome P450, NADPH-P450 reductase (RED), or both cytochrome P450 and RED.

47. The method of claim 46, wherein said bioreductive drug is Adriamycin, porfiromycin, mitomycin C, tirapazamine, indoloquinone E09, aziridinylnitroimidazole RB6145, dinitrophenylaziridine (CB1954), 2, 3, 5, 6-tetramethylbenzoquinone (TMQ), diaziquone (AZQ), the intercalator amine N-oxide AQ4N, the bioreducible DNA alkylator NSC646394 or the bioreducible DNA alkylator NSC658926.

48. The method of claim 44, wherein said cytochrome P450 gene is P450 2B6 and said bioreductive drug is tirapazamine.

49. A method for killing neoplastic cells in a mammal, said method comprising:

(a) administering to said mammal an agent that will decrease the activity or expression level of hepatic P450 reductase (RED) in said mammal;

(b) delivering a vector to said neoplastic cells, said vector comprising the nucleotide coding sequence of a gene encoding cytochrome P450 and the nucleotide coding sequence of a gene encoding RED;

(c) treating said neoplastic cells with a chemotherapeutic agent that is activated by the gene product of said cytochrome P450 gene; and

(d) killing said neoplastic cells.

50. The method of claim 49, wherein said agent that will decrease the activity or expression level of hepatic P450 reductase in said mammal is an anti-thyroid drug.

51. The method of claim 50, wherein said anti-thyroid drug is methimazole or propylthiouracil.

52. The method of claim 51, wherein said anti-thyroid drug is methimazole.

53. The method of claim 49, wherein said cytochrome P450 gene is P450 1A1, P450 1A2, P450 1B1, P450 2B1, P450 2B2, P450 2B4, P450 2B5, P450 2B6, P450 2B11, P450 2A6, P450 2C6, P450 2C8, P450 2C9, P450 2C11, P450 2C18, P450 2C19, P450 2D6, P450 2E1, P450 3A4, P450 3A5, P450 3A7, or P450 4B1.

54. The method of claim 49, wherein said chemotherapeutic agent is cyclophosphamide, ifosfamide, dacarbazine, procarbazine, thio-TEPA, etoposide (VP-16), 4-ipomeanol, 2-aminoanthracene, or tamoxifen.